Long the market leader in orthopedics, Zimmer has seen itself leap-frogged by companies formed out of the recent wave of consolidation in the orthopedic industry. Free of its long-time pharmaceutical parent, Bristol-Myers Squibb, through the largest spin-off in health care history, Zimmer is looking to capitalize on its independence to get into high growth market segments the company was previously precluded from entering, such as spine and biologicals. Despite not being a player in the fastest-growing segments of orthopedics, spine and sports medicine, Zimmer has been consistently producing outstanding financial results, benefiting in part from investors' current strong support of orthopedics as a whole. In this interview, Zimmer's chairman and CEO, J. Raymond Elliott discusses how the company plans to utilize innovative approaches including direct-to-consumer advertising and minimally-invasive techniques and devices to drive Zimmer back to prominence.
by Stephen Levin
When J. Raymond Elliott was named president of Zimmer (now Zimmer Holdings Inc. ) in November 1997, the orthopedics...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
